Da: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germania
Taschenbuch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Radium-223 dichloride (Ra-223) is an alpha particle-emitting radiopharmaceutical whose licensed indication in patients with castration-resistant prostate cancer with bone metastases (CRPCm) was modified in June 2018, due to the appearance of drug-drug interactions with common drugs in CRPCm such as abiraterone and prednisone/prednisolone. Thus, it was restricted to use in monotherapy or combination with luteinizing hormone-releasing hormone analogues, becoming third-line treatment in patients with CRPCm, for which evidence on its effectiveness and safety in this new context is lacking. 60 pp. Englisch. Codice articolo 9786206581642
Quantità: 2 disponibili
Da: AHA-BUCH GmbH, Einbeck, Germania
Taschenbuch. Condizione: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Radium-223 dichloride (Ra-223) is an alpha particle-emitting radiopharmaceutical whose licensed indication in patients with castration-resistant prostate cancer with bone metastases (CRPCm) was modified in June 2018, due to the appearance of drug-drug interactions with common drugs in CRPCm such as abiraterone and prednisone/prednisolone. Thus, it was restricted to use in monotherapy or combination with luteinizing hormone-releasing hormone analogues, becoming third-line treatment in patients with CRPCm, for which evidence on its effectiveness and safety in this new context is lacking. Codice articolo 9786206581642
Quantità: 1 disponibili
Da: moluna, Greven, Germania
Condizione: New. Codice articolo 1188787031
Quantità: Più di 20 disponibili
Da: buchversandmimpf2000, Emtmannsberg, BAYE, Germania
Taschenbuch. Condizione: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Radium-223 dichloride (Ra-223) is an alpha particle-emitting radiopharmaceutical whose licensed indication in patients with castration-resistant prostate cancer with bone metastases (CRPCm) was modified in June 2018, due to the appearance of drug-drug interactions with common drugs in CRPCm such as abiraterone and prednisone/prednisolone. Thus, it was restricted to use in monotherapy or combination with luteinizing hormone-releasing hormone analogues, becoming third-line treatment in patients with CRPCm, for which evidence on its effectiveness and safety in this new context is lacking.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 60 pp. Englisch. Codice articolo 9786206581642
Quantità: 1 disponibili